Multiple stents
IOP control good with one stent – and better with two or three


Roibeard O’hEineachain
Published: Wednesday, February 1, 2017

Antonio Maria Fea MD
In this present series of patients receiving a single stent or multiple stents as sole therapy, there was a sustained reduction in IOP with a reduction in drug burden in all patients through 30 monthsHowever, by 30 months the proportion requiring medication had risen to about 25% among those with only one stent, but remained unchanged in the other two treatment groups. The safety profile of the procedures was also favourable, Dr Fea said. There were no intraoperative or perioperative complications. In addition, postoperative best corrected visual acuity (BCVA) was comparable in the three groups and was 20/40 or better in nearly 80% of eyes. There was a postoperative loss of one or more lines of BCVA in four eyes in the one-stent group, three eyes in the two-stent group and four eyes in the three-stent group, although nine of these 11 eyes had BCVA of 20/40 or better. Dr Fea noted that the findings of his study appear to confirm previous clinical observations that, as standalone procedures, implantation of one iStent achieves long-term, stable IOP control, and use of two or three iStents results in further IOP lowering than that achieved with a single stent. The enhanced IOP reduction may be due not only to each stent providing additional drainage of the aqueous. It may also result from the increased chance surgeons have of placing a stent in an optimum position in relation to collector channels of Schlemm’s canal, he said. To optimise the placement of the iStent implants, Dr Fea and his associates have devised a means of localising the collector channels by using a special dye. However, whether this will improve outcomes will not be known until the completion of randomised control trials. “In this present series of patients receiving a single stent or multiple stents as sole therapy, there was a sustained reduction in IOP with a reduction in drug burden in all patients through 30 months,” he concluded. Antonio Maria Fea: antoniofea@interfree.it
Latest Articles
ESCRS Today 2025: Happy Anniversaries!
ESCRS celebrates milestones with pioneers in IOLs, LASIK, femtosecond lasers, and corneal transplantation.
ESCRS Today 2025: A Congress for Everyone
From YOs to families, the ESCRS Annual Meeting embraces full participation through inclusivity.
Beyond the Numbers
Empowering patient participation fosters continuous innovation in cataract surgery.
Thinking Beyond the Surgery Room
Practice management workshop focuses on financial operations and AI business applications.
Aid Cuts Threaten Global Eye Care Progress
USAID closure leads retreat in development assistance.
Supplement: ESCRS Clinical Trends Series: Presbyopia
Debate: FS-LASIK or KLEx for Hyperopia?
FS-LASIK has more of a track record, but KLEx offers advantages.
Four AI Applications Ready for Practice
Commercial offerings may save time, improve practice and research.
Perioperative Medication Regimens for Cataract Surgery
Randomised controlled clinical trial results provide evidence-based guidance.